Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CFO James William Rogers sold 23,030 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $45.97, for a total transaction of $1,058,689.10. Following the completion of the sale, the chief financial officer now directly owns 164,750 shares in the company, valued at $7,573,557.50. This trade represents a 12.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
James William Rogers also recently made the following trade(s):
- On Tuesday, February 18th, James William Rogers sold 31,780 shares of Tempus AI stock. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40.
- On Wednesday, February 5th, James William Rogers sold 8,712 shares of Tempus AI stock. The shares were sold at an average price of $67.57, for a total transaction of $588,669.84.
Tempus AI Stock Performance
Shares of TEM traded up $2.29 during trading hours on Wednesday, reaching $48.03. 11,624,616 shares of the company traded hands, compared to its average volume of 5,018,008. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business has a fifty day moving average price of $55.86 and a 200-day moving average price of $51.48. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $91.45.
Institutional Trading of Tempus AI
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on TEM shares. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Morgan Stanley lifted their target price on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Bank of America lifted their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Needham & Company LLC lifted their price objective on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Piper Sandler cut their price target on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $61.18.
View Our Latest Analysis on TEM
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
- Five stocks we like better than Tempus AI
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Why Are These Companies Considered Blue Chips?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- The Most Important Warren Buffett Stock for Investors: His Own
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.